Cocrystal Pharma Inc Cash Flow Conversion Efficiency
Cocrystal Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has a cash flow conversion efficiency ratio of -2.410x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.52 Million) by net assets ($1.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cocrystal Pharma Inc (2007–2025)
Cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2025. This chart illustrates how Cocrystal Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cocrystal Pharma Inc stock quote for real-time trading data and today's change.
Cocrystal Pharma Inc Cash Flow Conversion Ratio Explained
Cocrystal Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cocrystal Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cocrystal Pharma Inc ranked by their cash flow conversion efficiency. Also see COCP market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mostostal Warszawa S.A.
WAR:MSW
|
1.170x |
|
UTSTARCOM HLDGS DL-0015
F:UT5
|
N/A |
|
DigiCAP Co. Ltd
KQ:197140
|
0.067x |
|
Gabungan AQRS Bhd
KLSE:5226
|
-0.112x |
|
Glostrext Berhad
KLSE:0284
|
0.060x |
|
Flagship Investments Ltd
AU:FSI
|
-0.006x |
|
AGMO
KLSE:0258
|
0.001x |
|
GridAI Technologies Corp.
NASDAQ:GRDX
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cocrystal Pharma Inc from 2007 to 2025. Review Cocrystal Pharma Inc (COCP) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.33 Million | $-8.19 Million | -1.294x | +25.25% |
| 2024-12-31 | $9.52 Million | $-16.48 Million | -1.731x | -211.42% |
| 2023-12-31 | $26.38 Million | $-14.67 Million | -0.556x | -2.61% |
| 2022-12-31 | $39.57 Million | $-21.43 Million | -0.542x | -230.30% |
| 2021-12-31 | $77.55 Million | $-12.72 Million | -0.164x | +12.40% |
| 2020-12-31 | $52.51 Million | $-9.83 Million | -0.187x | -207.94% |
| 2019-12-31 | $25.71 Million | $-1.56 Million | -0.061x | +50.94% |
| 2018-12-31 | $66.89 Million | $-8.29 Million | -0.124x | -89.24% |
| 2017-12-31 | $105.40 Million | $-6.90 Million | -0.065x | +54.27% |
| 2016-12-31 | $102.32 Million | $-14.65 Million | -0.143x | -132.67% |
| 2015-12-31 | $167.59 Million | $-10.32 Million | -0.062x | +93.19% |
| 2014-12-31 | $6.65 Million | $-6.01 Million | -0.903x | -219.17% |
| 2013-12-31 | $-6.03 Million | $-4.57 Million | 0.758x | +84.47% |
| 2012-12-31 | $-3.58 Million | $-1.47 Million | 0.411x | +170.34% |
| 2011-12-31 | $-2.77 Million | $-420.95K | 0.152x | +105.45% |
| 2010-12-31 | $6.93K | $-19.34K | -2.791x | -506.59% |
| 2009-12-31 | $54.54K | $-25.10K | -0.460x | -30.68% |
| 2008-12-31 | $95.34K | $-33.58K | -0.352x | -51.65% |
| 2007-12-31 | $147.13K | $-34.17K | -0.232x | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more